Revvity 0, -, 250µci (9

Revvity 250 µCi quantity of CP 55940, [Side Chain-2,3,4-³H(N)]-, is available for your research. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity CP 55,940 is a synthetic cannabinoid that mimics the effects of naturally occuring tetrahydrocannabinol (THC). It acts as a full agonist at cannabinoid receptors type 1 and 2. These GPCRs are potential drug targets for a variety of diseases, including epilepsy, cancer, obesity, and osteoporosis. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET1051: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Chiang, Y.-C. and Chen, J.-C. (2007), The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. Journal of Neurochemistry, 103: 2505–2517.Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, González-Maeso J, et Al. (2013), The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology, 38: 2373–2384.